• Regeneron executives Leonard Schleifer, George Yancopoulos, Marion McCourt, Chris Fenimore attended Q1 2026 earnings call on April 29.
• Non-GAAP diluted EPS rose 15% to USD 9.47 on total revenue up 19% to USD 3.6 billion.
• Management highlighted Dupixent constant-currency net sales growth of 31% to USD 4.9 billion, noting broad-based demand across indications.
• Company flagged EYLEA HD US net sales up 52% to USD 468 million, expecting FDA action this quarter on one or both pending pre-filled syringe applications.
• Board authorized new USD 3 billion share repurchase program, lifting available repurchase capacity to about USD 3.4 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on May 01, 2026, and is solely responsible for the information contained therein.